Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF -2-
January 15, 2001
- CPAC to Become Pharmaceutical Affairs and Food Sanitation Council
January 15, 2001
- Banyu Confirms Efficacy, Safety of Simvastatin in Clinical Trail
January 15, 2001
- CAPC's Executive Committee Recommends Approval of 16 Active Ingredients
January 15, 2001
- Takepron Approved for Maintenance Therapy of Recurrent Reflux Esophagitis
January 1, 2001
- Business of Major Drugstore Chain Operators Continues to Expand
January 1, 2001
- JPMA to Work More Closely with Patients' Organizations
January 1, 2001
- Matsumotokiyoshi: Consolidated Half-year Sales Reach ¥115 Bil.
January 1, 2001
- Health Minister Stresses Need for Government to Support Genomic Research: 1st JPMA Forum
January 1, 2001
- Ten More Items to Be Allowed to Be Advertised by Medical Facilities
January 1, 2001
- BUSINESS NEWS IN BRIEF
January 1, 2001
- Tsuruha Acquires Drug Tomato in Iwate
January 1, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 1, 2001
- Kaletra Included in NHI List
January 1, 2001
- Fukuda Denshi to Charge Customers for Maintenance Services
January 1, 2001
- Welfide Licenses Glaucoma Treatment to Senju
January 1, 2001
- NHI Price Listing of Relenza, Tamiflu No Sooner Than Mid February
January 1, 2001
- OTC NEWS IN BRIEF
January 1, 2001
- New Year's Greeting
January 1, 2001
- Ministries, Agencies to Be Reorganized
January 1, 2001
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…